# Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)

> **NCT03178643** · PHASE4 · COMPLETED · sponsor: **Duke University** · enrollment: 246 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **DRUG:** Proguanil Oral Tablet
- **DRUG:** Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)
- **DRUG:** Dihydroartemisinin-Piperaquine (DP)

## Key facts

- **NCT ID:** NCT03178643
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-23
- **Primary completion:** 2020-12-16
- **Final completion:** 2020-12-16
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178643, "Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03178643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*